Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) EPS (Weighted Average and Diluted): 2018-2024

Historic EPS (Weighted Average and Diluted) for Denali Therapeutics (DNLI) over the last 7 years, with Dec 2024 value amounting to -$2.57.

  • Denali Therapeutics' EPS (Weighted Average and Diluted) rose 21.84% to -$0.68 in Q4 2024 from the same period last year, while for Dec 2024 it was -$2.58, marking a year-over-year decrease of 136.70%. This contributed to the annual value of -$2.57 for FY2024, which is 142.45% down from last year.
  • Per Denali Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$2.57 for FY2024, which was down 142.45% from -$1.06 recorded in FY2023.
  • Denali Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.63 during FY2020, with a 5-year trough of -$2.60 in FY2022.
  • Over the past 3 years, Denali Therapeutics' median EPS (Weighted Average and Diluted) value was -$2.57 (recorded in 2024), while the average stood at -$2.08.
  • As far as peak fluctuations go, Denali Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 130.43% in 2020, and later plummeted by 479.37% in 2021.
  • Yearly analysis of 5 years shows Denali Therapeutics' EPS (Weighted Average and Diluted) stood at $0.63 in 2020, then slumped by 479.37% to -$2.39 in 2021, then dropped by 8.79% to -$2.60 in 2022, then spiked by 59.23% to -$1.06 in 2023, then tumbled by 142.45% to -$2.57 in 2024.